KRAS and metastatic neoplasm: There was enrichment of <i>KRAS</i><sup><i>G12D</i></sup> mutation in metastatic tumors (34% vs 24%, OR: 1.7, 95% CI 1.2-2.4, p=0.001) and enrichment of <i>KRAS</i><sup><i>G12R</i></sup> in well and moderately differentiated tumors (14% vs 9%, OR: 1.7, 95% CI 1.05-2.99, p=0.04).